A prior study in metastatic HER2-positive breast cancer found differences in disease-specific survival and overall survival between invasive ductal carcinoma and invasive lobular carcinoma, depending on the site of metastatic involvement [5]. This evidence concerns the gene ERBB2 and invasive ductal breast carcinoma.